Covidien Announces Results from 2013 Annual General Meeting
DUBLIN -- March 20, 2013
Covidien plc (NYSE: COV) announced the results from today’s Annual General
Meeting. Eight proposals were on the meeting agenda:
*Election of Directors
*Appointment of Independent Auditors
*An advisory vote to approve the Company’s executive compensation
*Approval of the amended and restated Covidien Stock and Incentive Plan
*Authorization of the Company and/or any subsidiary to make market
purchases of Company shares
*Authorization of the reissue price range of treasury shares
*Amendment of the Company’s Articles of Association to expand the authority
to execute instruments of transfer, and
*An advisory vote on the creation of distributable reserves for
At the meeting, shareholders elected all 10 nominees, each of whom currently
serves on Covidien’s Board of Directors. They are: José E. Almeida, Joy A.
Amundson, Craig Arnold, Robert H. Brust, John M. Connors, Jr., Christopher J.
Coughlin, Randall J. Hogan, III, Martin D. Madaus, Dennis H. Reilley and
Joseph A. Zaccagnino. In addition, the Directors elected Mr. Reilley to be the
Lead Director, replacing Timothy M. Donahue, who did not stand for reelection
to the Board.
Shareholders also approved the appointment of Deloitte & Touche LLP to serve
as the Company’s independent auditors, and, in an advisory vote, approved the
Company’s executive compensation. Shareholders approved the amended and
restated Covidien Stock and Incentive Plan, authorized Covidien and/or any of
its subsidiaries to make market purchases of Company shares and authorized the
price range at which the Company can reissue shares it holds as treasury
shares. In addition, shareholders also approved an amendment to Covidien’s
Articles of Association to expand the authority to execute instruments of
transfer and, in an advisory vote, approved the creation of distributable
reserves for Mallinckrodt plc.
Covidien is a leading global healthcare products company that creates
innovative medical solutions for better patient outcomes and delivers value
through clinical leadership and excellence. Covidien manufactures, distributes
and services a diverse range of industry-leading product lines in three
segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012
revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70
countries, and its products are sold in over 140 countries. Please visit
www.covidien.com to learn more about our business.
Bruce Farmer, 508-452-4372
Coleman Lannum, CFA, 508-452-4343
Todd Carpenter, 508-452-4363
Press spacebar to pause and continue. Press esc to stop.